Regulatory Affairs
CPHI Milan 2026: what we took away from three days in Milan
Our team spent three days at CPHI Milan. Here is what stood out and what it means for...
Expert perspectives from the M.P.C.A. International team on Regulatory Affairs, Pharmacovigilance, GMP/GDP and market access in the Benelux.
Featured
On 30 October 2026, two new implementing decrees were published, marking the first step in the simplification of Belgian medicines pricing regulations. The measures aim to accelerate procedures, reduce administrative...
Read full article
Regulatory Affairs
Our team spent three days at CPHI Milan. Here is what stood out and what it means for...
Regulatory Affairs
The CBG-MEB is modernising its registration systems: new case numbers, digital signatures and submissions only via Common Repository...
Regulatory Affairs
Biotech Act, MDR/IVDR revision, Critical Medicines Act, new EU Pharmaceutical Legislation and stricter advertising rules: five initiatives to...
GDP & Distribution
On 18 July 2026 the Council of Ministers approved the draft royal decree introducing the Stock Monitoring Tool....
GDP & Distribution
A wholesaler was refused a GDP certificate after missing agreed CAPA deadlines. Why execution, not the plan, decides...
Cosmetics
Three EU regulatory changes for food supplements and cosmetics: harmonised nutrient levels, Belgian rules, and the Omnibus VIII...
Our team of specialists is ready to support you — from regulatory strategy and pharmacovigilance to market access and quality assurance.